Eisai (4523) Stock Overview
Engages in the research and development, manufacture, sale, and import and export of pharmaceuticals in Japan. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 4/6 |
| Financial Health | 4/6 |
| Dividends | 4/6 |
4523 Community Fair Values
Create NarrativeSee what 6 others think this stock is worth. Follow their fair value or set your own to get alerts.
Eisai Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥4,538.00 |
| 52 Week High | JP¥6,142.00 |
| 52 Week Low | JP¥3,463.00 |
| Beta | -0.18 |
| 1 Month Change | 8.05% |
| 3 Month Change | 9.59% |
| 1 Year Change | -25.84% |
| 3 Year Change | -20.30% |
| 5 Year Change | -51.82% |
| Change since IPO | 178.65% |
Recent News & Updates
Eisai's (TSE:4523) Dividend Will Be ¥80.00
Aug 25
Eisai Co., Ltd. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Aug 08Recent updates
Eisai's (TSE:4523) Dividend Will Be ¥80.00
Aug 25Eisai Co., Ltd. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Aug 08Eisai (TSE:4523) Will Pay A Dividend Of ¥80.00
Jul 23Eisai (TSE:4523) Is Due To Pay A Dividend Of ¥80.00
Jul 09Eisai's (TSE:4523) Solid Profits Have Weak Fundamentals
Jun 22Here's What Analysts Are Forecasting For Eisai Co., Ltd. (TSE:4523) After Its Annual Results
May 18Is Eisai (TSE:4523) A Risky Investment?
Apr 27Eisai (TSE:4523) Is Due To Pay A Dividend Of ¥80.00
Mar 15Eisai (TSE:4523) Will Pay A Dividend Of ¥80.00
Mar 01Eisai (TSE:4523) Will Pay A Dividend Of ¥80.00
Feb 12Results: Eisai Co., Ltd. Exceeded Expectations And The Consensus Has Updated Its Estimates
Feb 11Eisai (TSE:4523) Has Announced A Dividend Of ¥80.00
Jan 28Eisai (TSE:4523) Is Due To Pay A Dividend Of ¥80.00
Jan 14Here's Why Eisai (TSE:4523) Can Manage Its Debt Responsibly
Jan 13Eisai Co., Ltd.'s (TSE:4523) Share Price Matching Investor Opinion
Dec 26Eisai (TSE:4523) Is Paying Out A Dividend Of ¥80.00
Dec 05
LEQEMBI's Global Expansion And Innovations Propel Revenue And Market Growth
LEQEMBI's global rollout in key regions is poised to drive significant revenue growth through market expansion and adoption.Eisai (TSE:4523) Is Paying Out A Dividend Of ¥80.00
Nov 21Earnings Troubles May Signal Larger Issues for Eisai (TSE:4523) Shareholders
Nov 15Results: Eisai Co., Ltd. Exceeded Expectations And The Consensus Has Updated Its Estimates
Nov 12Is Eisai (TSE:4523) Using Too Much Debt?
Oct 15Eisai (TSE:4523) Is Paying Out A Dividend Of ¥80.00
Sep 20Eisai (TSE:4523) Has Affirmed Its Dividend Of ¥80.00
Sep 05Shareholder Returns
| 4523 | JP Pharmaceuticals | JP Market | |
|---|---|---|---|
| 7D | -3.0% | -1.5% | -0.7% |
| 1Y | -25.8% | -15.7% | 13.2% |
Return vs Industry: 4523 underperformed the JP Pharmaceuticals industry which returned -15.7% over the past year.
Return vs Market: 4523 underperformed the JP Market which returned 14.4% over the past year.
Price Volatility
| 4523 volatility | |
|---|---|
| 4523 Average Weekly Movement | 3.6% |
| Pharmaceuticals Industry Average Movement | 3.6% |
| Market Average Movement | 3.3% |
| 10% most volatile stocks in JP Market | 7.5% |
| 10% least volatile stocks in JP Market | 1.7% |
Stable Share Price: 4523 has not had significant price volatility in the past 3 months compared to the JP market.
Volatility Over Time: 4523's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1941 | 10,917 | Haruo Naito | www.eisai.co.jp |
Eisai Co., Ltd. engages in the research and development, manufacture, sale, and import and export of pharmaceuticals in Japan. It offers Dayvigo, for the treatment of insomnia; LEQEMBI is a humanized immunoglobulin gamma 1 (IgG1); Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; and Halaven, an anticancer agent for the treatment of breast cancer. The company also provides Methycobal for the treatment of peripheral neuropathy; Jyseleca, a janus kinase inhibitor; Goofice for chronic constipation; Fycompa, an antiepileptic agent; Pariet, a proton-pump inhibitor; Aricept, treatment for dementia; and Chocola BB plus for the preparation vitamin B2.
Eisai Co., Ltd. Fundamentals Summary
| 4523 fundamental statistics | |
|---|---|
| Market cap | JP¥1.28t |
| Earnings (TTM) | JP¥50.33b |
| Revenue (TTM) | JP¥803.02b |
Is 4523 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4523 income statement (TTM) | |
|---|---|
| Revenue | JP¥803.02b |
| Cost of Revenue | JP¥171.65b |
| Gross Profit | JP¥631.37b |
| Other Expenses | JP¥581.05b |
| Earnings | JP¥50.33b |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
Nov 05, 2025
| Earnings per share (EPS) | 178.53 |
| Gross Margin | 78.62% |
| Net Profit Margin | 6.27% |
| Debt/Equity Ratio | 28.0% |
How did 4523 perform over the long term?
See historical performance and comparisonDividends
Does 4523 pay a reliable dividends?
See 4523 dividend history and benchmarks| Eisai dividend dates | |
|---|---|
| Ex Dividend Date | Sep 29 2025 |
| Dividend Pay Date | Nov 19 2025 |
| Days until Ex dividend | 29 days |
| Days until Dividend pay date | 80 days |
Does 4523 pay a reliable dividends?
See 4523 dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/08/29 18:48 |
| End of Day Share Price | 2025/08/29 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Eisai Co., Ltd. is covered by 26 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Atsushi Seki | Barclays |
| Koichi Mamegano | BofA Global Research |
| Aaron Ho | CFRA Equity Research |